According to incomplete statistics from Innovation Radar, last week (August 25 to August 31)Global Health Sector Discloses 26 Financing Events with a Total Amount of Nearly $6.5 BillionAmong them, the cell and gene therapy (CGT) field has been highly active, with multiple companies gaining capital favor through innovations in delivery systems, breakthroughs in cancer treatment, and advancements in rare disease therapies. Additionally, fields such as protein degradation therapy and RNA therapy have also secured financing.

In the field of cell therapy,Wugen Becomes One of the Most Noticed Companies Last Week with $115 Million in Large-Scale Financing. Developed by the companyTargeted CD47 Allogeneic CAR-T Product WU-CART-007Using CRISPR/Cas9 gene editing technology, knockoutCD7AndTRACGenes, thereby preventing CAR-T cells from attacking each other and reducing the risk of graft-versus-host disease (GvHD). Wugen plans to submit a Biologics License Application (BLA) in 2027 for the treatment of T-cell malignancies.

Rui Zheng Gene Obtains $75 Million Series A Financing. The company focuses onDevelopment of In Vivo Gene Editing Technologies and Products Based on LNP and Other Non-Viral VectorsThe core pipeline ART001 for the treatment of the rare disease transthyretin amyloidosis received IND approval in China and the United States in July and August 2024, respectively, and is currently undergoing Phase 1/2a clinical trials in China. Another R&D product of the company, ART002, which targets PCSK9, is currently conducting IIT clinical research for familial hypercholesterolemia.

Drug delivery systems face challenges in efficiency and safety, which is why delivery technology has become one of the key areas for industry investment. For example,Hongxin Bio Raises Nearly RMB 100 Million in Pre-A+ Round FinancingHonest Biotech is a company focused on the development of nucleic acid drug delivery and innovative therapeutic mRNA drugs. The company has developed a library of ionizable amino lipids, with its core lipid (ILB3132) already commercialized, and has made breakthroughs in its engineered cell-targeting delivery platform. It is reported that the In vivo CAR-T pipeline developed based on this platform has completed the first patient dosing, achieving CAR-T reprogramming and B-cell depletion, demonstrating good safety and preliminary clinical efficacy.

In addition, focusing on protein degradation therapy,Plexium Secures $60.1 Million in Financing, its oral CRBN molecular glue degrader PLX-4545 targeting IKZF2 has entered Phase 1 clinical research, while another candidate drug, PLX-61639, targets the SMARCA2 protein through a synthetic lethality mechanism, offering a new treatment option for patients with SMARCA4-mutant cancers.

In the field of central nervous system,Leal Therapeutics Completes $30 Million Series A FinancingThe company is committed to developing effective treatments for neuropsychiatric and neurodegenerative diseases by correcting metabolic imbalances in the brain. The core pipeline includes LTX-001, an orally administered, brain-penetrating small molecule drug that targets excessive glutamate by inhibiting the mitochondrial enzyme glutaminase, addressing a range of psychiatric disorders including schizophrenia, bipolar disorder, major depressive disorder, and amyotrophic lateral sclerosis (ALS).

In addition, other companies such asXinhua Biotech、Plexium, ADC Drug NewcomerAikori、Hantong MedicalAll have completed financing, as detailed in the table below.

Readers, please star ⭐Chuangjianhui to receive push notifications第一时间收到推送.

Disclaimer: This article is for informational exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share to their WeChat Moments. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Chuangjian Hui"Contact us by leaving a message on the WeChat Official Account.

More Data Content Recommended

Click "InSee", Sharing Creagent Health's Latest Developments